KDR and neoplasm: Gal-1 binds to VEGFR2 leading to unresponsiveness to anti-VEGF therapy, and disruption of the Gal-1-VEGFR2 axis promotes vessel normalization, immune cell recruitment, tumor growth inhibition and restores sensitivity to anti-angiogenic therapy (229).